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Abstract
Glucocorticoids are well -known apoptotic agents in
certain classes of lymphoid cell malignancies. Reduc-
tion of intracellular polyamine levels by use of inhibitors
that block polyamine synthesis slows or inhibits growth
of many cells in vitro. Several such inhibitors have
shown efficacy in clinical trials, though the toxicity of
some compounds has limited their usefulness. We have
tested the effects of combinations of the glucocorticoid
dexamethasone (Dex) and two polyamine inhibitors,
difluoromethylornithine (DFMO) and methyl glyoxal bis
guanylhydrazone (MGBG), on the clonal line of human
acute lymphoblastic leukemia cells, CEM-C7-14. Dex
alone kills these cells, though only after a delay of at
least 24 hours. We also evaluated a partially glucocorti-
coid-resistant c-Myc–expressing CEM-C7-14 clone.
We show that Dex downregulates ornithine decarbox-
ylase (ODC), the rate- limiting enzyme in polyamine
synthesis. Pretreatment with the ODC inhibitor DFMO,
followed by addition of Dex, enhances steroid-evoked
kill slightly. The combination of pretreatment with
sublethal concentrations of both DFMO and the inhibitor
of S -adenosylmethionine decarboxylase, MGBG, fol-
lowed by addition of Dex, results in strong synergistic
cell kill. Both the rapidity and extent of cell kill are
enhanced compared to the effects of Dex alone. These
results suggest that use of such combinations in vivo
may result in apoptosis of malignant cells with lower
overall toxicity.
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Introduction
The three physiological polyamines — putrescine, spermi-
dine, and spermine — are all positively charged polycations
at cellular pH and presumably function as stabilizing agents
of RNA, DNA, or negatively charged proteins. Cells regulate
polyamine pool sizes through synthesis, active transport,
degradation, and interconversions [1,2 ]. The active transport
system permits exogenous polyamines to be recruited as
needed by the cell [3 ]. Polyamines are required for cells to
cycle, and these complicated, tightly regulated mechanisms
allow cells to adjust polyamine levels constantly as growth
dictates [4]. The rate- limiting enzyme in the polyamine
synthetic pathway is ornithine decarboxylase (ODC), which
is responsible for putrescine synthesis. Spermidine and
spermine are produced from putrescine by the actions of
S -adenosylmethionine decarboxylase (AdoMetDC) and
spermidine/spermine synthase. ODC activity is required for
cells to proceed into S-phase of the cell cycle [5 ] and is
under multilevel, strict regulation [6,7 ]. AdoMetDC contrib-
utes to the production of spermidine and spermine by
facilitating the formation of decarboxylated S -adenosylme-
thionine, the amino propyl donor for spermidine and spermine
synthases. Methyl glyoxal bis guanylhydrazone (MGBG), a
structural analog of spermidine, is a potent reversible inhibitor
of AdoMetDC. Alone, MGBG effectively lowers spermidine
and spermine levels while causing an accumulation of
putrescine by several mechanisms [8].
Because of their importance in many cellular functions,
polyamines have long been the focus of research as potential
chemotherapeutic agents [8 ]. Combinations of difluorome-
thylornithine (DFMO) and MGBG have proven to be more
effective at halting cell growth than either drug alone.
Synergism between the two has been reported [8-10,11-
13] when cells were incubated for a period of time with
combinations of the inhibitors which allow polyamine pools to
drop. Although in vivo outcomes with the combination have
sometimes shown heightened toxicity [14], several studies
have found the polyamine inhibitor drug combination effective
in treatment of cancers in mice and humans [9-11,12,13].
The ability of glucocorticoids to affect cell growth has
generated much interest to cancer investigators over the
years [15-17,18]. We have shown that transcriptional
downregulation of the proto-oncogene c-myc is a critical
signal in the pathway of the glucocorticoid-evoked apoptosis
of CEM cells [19,20]. The odc gene contains E box binding
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sites for c-Myc and is a c-Myc transcriptional target [5,21].
We demonstrate here that c-Myc levels are suppressed by
glucocorticoids, as well as cellular odcmRNA, protein levels,
and ODC activity. Historically, it has been shown that direct
inhibition of ODC through the use of DFMO, a specific,
irreversible inhibitor of the enzyme, slows cell growth [22]. In
several systems, DFMO reduces putrescine and spermidine
levels dramatically through irreversible inhibition of ODC;
however, spermine levels show an increase. Spermine has
been implicated as a possible salvage polyamine, conver-
tible to the precursor polyamines as the need arises [8].
There has been only limited data published on the
combination of these inhibitors with glucocorticoids in
malignant cells [23]. This study has centered on the ability
of polyamine inhibitors to influence glucocorticoid- induced
apoptosis in human lymphoblastic leukemic CEM cells. We
report here that the synthetic glucocorticoid dexamethasone
(Dex) causes a reduction in ODC activity, mRNA, and
protein in CEM cells. Treatment of these cells with a
combination of low nonlethal concentrations of DFMO and




The human CCRF-CEM cell line was grown from a
patient with acute lymphoblastic leukemia [24]. The gluco-
corticoid-sensitive CEM-C7-14 clone was subcloned from
the original, sensitive clone CEM-C7 [25]. To obtain c-
Myc–expressing cells, CEM-C7-14 cells were transfected
with pBpuroMycER, which contains the human c-Myc
protein fused to the modified ligand-binding domain of the
murine estrogen receptor  [26]. Selection in puromycin
gave rise to a mass culture of cells partially resistant to Dex;
clone CEM-MycER-22 was chosen for use herein. All cells
were grown in RPMI 1640 medium (Cellgro; Media Tech,
Herndon, VA), pH 7.4, with 5% heat- inactivated fetal bovine
serum (FBS) (Atlanta Biologicals, Norcross, GA) at 378C in
a humidified atmosphere of 95% air, 5% CO2. Subculturing
at regular intervals insured logarithmic growth. Viable cell
numbers were determined by Trypan blue dye (Sigma-
Aldrich, St. Louis, MO) exclusion using a hemacytometer,
averaging triplicate counts at each data point. All experi-
ments were initiated at 1105 cells /ml. All reagents, unless
otherwise identified, were from Sigma-Aldrich.
Extensive preliminary experiments (not shown) indicated
that addition of the polyamine pathway inhibitors simulta-
neously with Dex was less effective than pretreatment with
DFMO (Merrell Dow Pharmaceuticals, Cincinnati, OH) and
MGBG followed by Dex. To find optimum concentrations of
the polyamine pathway inhibitors, DFMO was tested
between 0.1 and 1.0 mM, and MGBG between 50 nM and
25 M. The most effective and least toxic concentrations
proved to be 0.5 mM DFMO and 0.5 M MGBG dissolved in
isotonic phosphate-buffered saline (PBS) without Ca2+ or
Mg2+ , pH 7.4. For all the experiments herein, we employed
the following standard protocol, unless noted otherwise.
Cells were pretreated for 24 hours with both inhibitors before
Dex was added to a final concentration of 107 M and
0.1% ethanol. Control cultures all received ethanol and
PBS equivalent to the volume used to introduce DFMO,
MGBG, and Dex.
ODC Activity
A total of 5106 cells were collected by centrifugation at
250g for 10 minutes at 228C. The pellet was washed once by
resuspension in 228C PBS and repelleted. The cells were
suspended in 500 l of lysis cocktail [0.05 M sodium–
potassium phosphate buffer, pH 7.2, 0.1 mM EDTA, 1 mM
DTT, 0.1mMphenylmethylsulfonyl fluoride, 0.4mMpyridoxal
phosphate (Calbiochem, San Diego, CA) ]. After brief probe
sonication, to disrupt cell membranes, samples were dis-
tributed in 200-l aliquots to glass tubes fitted with stoppers
fromwhich filter papers saturatedwith 1Mhyamine hydroxide
were suspended. An equivalent volume of lysis cocktail was
used as a reagent blank. A 20-l aliquot from a stock solution
containing 31 Ci /ml of L -14C- labeled ornithine (Amersham
Pharmacia Biotech, Piscataway, NJ) and 5 mM unlabeled
ornithine in deionized water was added to each tube. After
incubating at 378C for 60 minutes with agitation, a 500-l
aliquot of 1 M citric acid was added to stop the reaction. The
tube was further incubated at 228C for 90 minutes, and
radioactivity on the filters was estimated in an organic
scintillation cocktail and counted on a LS5801 liquid
scintillation counter (Beckman Instruments, Palo Alto, CA).
Isolation and Analysis of RNA
Total cellular RNA was isolated from cell pellets of
approximately 8107 cells, washed as above with sterile,
48C PBS. To each pellet, 3 ml of TRIzol reagent (Gibco/
BRL, Grand Island, NY) was added, and after mixing, the
sample was processed according to the manufacturer’s
instructions, with minor modifications. The resulting RNA
was dissolved in RNAse- free water. The RNA (20 g/ lane)
was separated in agarose–formaldehyde gels, transferred to
a PROTRAN nitrocellulose membrane ( Intermountain Sci-
entific, Kaysville, UT), and hybridized to a 32P- labeled ( ICN,
Costa Mesa, CA) odc DNA fragment in QuikHyb hybrid-
ization solution (Stratagene, La Jolla, CA). The gel was dried
and exposed to a Phosphorimager screen (Molecular
Dynamics, Sunnydale, CA) and the densities of the odc
mRNA bands quantified relative to the 18S and 28S
ribosomal RNA bands using Image Quant software (version
3.3) from Molecular Dynamics.
Immunoblot Analysis
From cultures initially in log growth, 1107 CEM-C7-14
cells were harvested by centrifugation at 250g for 10
minutes, 48C, at 0, 24, and 48 hours after treatment with
1 M Dex. The cells were resuspended in 48C PBS, re-
pelleted, and taken up in lysis buffer: 50 mM Tris–HCl, pH
7.4, 150 mM NaCl, 1 mM EGTA, 1% Nonidet P-40, 20 M
leupeptin, and 400 M 4-[2-aminoethy]benzensulfonyl
fluoride. The cellular lysates were centrifuged at 30,000 rpm
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for 30 minutes at 48C using a Beckman TL-100 ultracen
trifuge (Beckman Instruments). The supernatants were
removed to fresh 1.5-ml microcentrifuge tubes and a Bio-
Rad (Hercules, CA) protein assay kit was used to estimate
the protein concentration of the extract. Before electro-
phoresis, 2-mercaptoethanol (Bio-Rad) was added to all
samples to a final concentration of 5%. Samples of the whole
cell extracts containing 50 g of protein per lane were
electrophoresed in 10% polyacrylamide minigels (Bio-Rad)
containing SDS and transferred to nylon membranes (Bio-
Rad) using a semidry electroblotter ( Integrated Separation
Systems, Hyde Park, MA). After incubation in 5% nonfat dry
milk powder in PBS for 2 hours at 228C, the membranes
were incubated with gentle rocking for 16 hours at 48C in a
solution of 5% powdered nonfat milk in PBS plus a
monoclonal ODC antibody derived from ODC-29 hybridoma
(Sigma-Aldrich). After six 10-minute washes with PBS at
228C, the membranes were incubated for 2 hours at 228C
with a horseradish peroxidase goat /anti–mouse secondary
antibody (Bio-Rad). After washing the membrane as above,
it was saturated with the horseradish peroxide substrate ECL
(Amersham Pharmacia Biotech) and exposed to photo-
graphic film (Eastman Kodak, Rochester, MY) using various
times of exposure to assure that evaluations for quantifica-
tion of the signals were within the linear response range. The
densitometric analysis of ODC protein was performed using
an Image Analyzer (Applied Imaging, Santa Clara, CA).
Determination of Putrescine, Spermidine, and Spermine
Concentration by HPLC
The HPLC procedure was modified from those of Merali
and Clarkson [27] and of Weiss et al. [28]. Briefly, standards
were dissolved in 0.2 M borate buffer, pH 8.8 (0.2 M sodium
hydroxide, 0.2 M boric acid, and 1 mM EDTA), at a
concentration of 1105 M, fluorescence tagged with
AccQFluor reagent (Waters, Milford, MA), and fractionated
on a C8 Microsorb-MV (1504.6 mm id) column with a 100-
A˚ pore size (Varian Analytical Instruments, Walnut Creek,
CA). The fractions were evaluated on a Hewlett Packard
HPLC, Series II 1090, AminoQuant with a programmable
fluorescence detector, 1046A using ChemStation software,
Dos series (Hewlett Packard, Palo Alto, CA). Unknowns
were quantified by comparison to known standards, and
experimental repeatability was determined after five injec-
Figure 1. Dex regulation of ornithine decarboxylase. Panel A: ODC activity. CEM-C7 cells were cultured in RPMI 1640 with 5% FBS, plus 0.1% ethanol only —
Control cells (^ ) — or with 1 M Dex delivered in ethanol (5 ) for 48 hours. ODC activity was determined at various times. The error bars show standard
deviations, n=3. Where no bars are seen, the standard deviation fell within the dimension of the symbol. Panel B: Northern blot showing specific odc mRNA bands.
There were no significant variations in the corresponding 18S and 28S ribosomal RNA bands on the same filter. Panel C: Immunoblots showing the reaction with a
monoclonal antibody to ODC in CEM-C7 -14 cell lysates from cells cultured in RPMI 1640 with 5% FBS and treated for 0, 24, and 48 hours with 1 M Dex. Data
shown in panels B and C were reproduced in several experiments.
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tions. To prepare cell lysates, 6.4106 cells were pelleted at
250g for 10 minutes, 48C, resuspended once in 48C PBS,
repelleted, and suspended in 100 l of 50 mM borate buffer,
pH 7.4 (50 mM sodium hydroxide, 50 mM boric acid, and
1mMEDTA). The samples were lysed by three freeze–thaw
cycles of 808C and then 378C, and debris was pelleted at
12,000 rpm for 10 minutes at 48C in a Beckman Microfuge
Lite centrifuge. Protein was removed by precipitation with
trichloroacetic acid and centrifugation. The clarified samples
were then filtered through a 0.22-m syringe filter (Millipore,
Bedford, MA). For analysis, HPLC sample tubes (Supelco,
Bellefonte, PA) were set up with a mixture of 30 l of 0.2 M
borate buffer, pH 9.3, and 10 l of 0.2 M borate buffer, pH
8.8. A 10-l aliquot of the internal standard (1105 M 1,7-
diaminoheptane) and a 10-l aliquot of experimental cell
lysate were added, followed by a 20-l aliquot of AccQFluor
reagent. The samples were incubated at 558C for 10 minutes
before HPLC analysis. A sample volume of 20 l was
injected onto the column, and the polyamine profile was
characterized using a flow rate of 1 ml /min at 378C,
excitation=250 nm and emission=395 nm, eluting with
AccQTag Eluent A/acetonitrile (Waters; Burdick and Jack-
son, Muskegon, MI) as a linear gradient. All samples were
analyzed within 24 hours of derivation. Determination of
statistical significance was done using a t - test, and P values
of less than .05 were considered significant.
Phosphatidylserine Membrane Eversion
Cell pellets were prepared following the instructions of the
Annexin-V-FITC kit from PharMingen (San Diego, CA). A
5-l aliquot of Annexin-V-FITC and 10 l of 7-AAD stain
were added to 1105 cells and incubated in the dark at 258C
for 15 minutes. A 400-l aliquot of binding buffer was added
and 20,000 cells were analyzed for Annexin-V (yellow/
green) and 7-AAD (red) positive cells by flow cytometry
using a 488-nm excitation and a 515-nm bandpass filter for
fluorescein detection and a filter >600 nm for 7-AAD
detection on a FACScan (Becton Dickinson, San Jose,
CA). Doublets and cell aggregates were gated out and only
the singlet cell population was analyzed.
JC-1 Staining of Depolarized Mitochondrial Membranes
CEM-C7-14 and CEM-MycER-22 cells were stained
following the protocol of Bradberry et al. [29] using 5,50,6,60 -
Figure 2. Polyamine levels after treatment with polyamine inhibitors, Dex alone, or both in combination. CEM-C7 -14 (A,B ) and CEM-MycER-22 (C,D ) cells were
cultured in RPMI 1640 plus 5% FBS with 100 nM Dex for 48 hours (A,C ) and 72 hours (B,D ). As a control, the cultured cells were treated with vehicle only. In each
Dex plus inhibitor - treated sample, 0.5 mM DFMO and 0.5 MMGBG were added 24 hours before Dex. Cell lysates of 1.010 5 cells were evaluated by HPLC and
normalized with the internal standard 1,7 - diaminoheptane. In each experiment, each time point was evaluated with a minimum of duplicate independent samples,
n=4–6. Statistical analyses were done using a t - test, and P values of less than .05 were considered to be significant.
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tetrachloro - 1,10,3,30 - tetraethylbenzimidazolylcarbocyanine
iodide (JC-1) fromMolecular Probes (Eugene, OR). Briefly,
1106 cells were suspended in 130 l, 378C RPMI 1640 plus
5% FBS. A working solution of 250 l of JC-1 (1 mg/ml
diluted 1/50 in PBS) was added and the cells were incubated
at 378C in an air /CO2 incubator for 30 minutes. After one
228C PBS wash, 20,000 cells were analyzed for intact
mitochondria by flow cytometry using a FACScan. Green
Figure 3. Apoptotic events after three - drug treatment, cell loss, phosphatidyl serine membrane eversion, and loss of mitochondrial function. CEM-C7 -14 cells were
treated according to the standard protocol. Panel A: The number of viable cells was determined by counting cells that excluded trypan blue dye exposure to vehicle
only (^), DFMO plus MGBG added at 0 hours (& ), Dex added at 24 hours (4 ), DFMO plus MGBG added at 0 hours plus Dex added at 24 hours ( ), n=3. Error
bars show 1 SD. Where no bars are seen, 1 SD fell within the symbols. The data in (B ) and (C ) were obtained from cells treated by the same protocol as in (A ), but
data collection began at 42 hours, 18 hours after Dex treatment. In panel B after the same protocol, cells were evaluated by Annexin -V -FITC /7 -AAD staining at 42,
48, 59, and 64 hours to determine the enversion of the phosphatidylserine portions of the cell membrane. In panel C, cells were evaluated by JC -1 staining at 42, 48,
59, 64, 72, and 96 hours. Data for panels B and C were obtained by FACScan analyses.
Figure 4. Cell cycle distribution andaccumulation of subdiploid cells.CEM-C7 -14 cellswere treatedaccording to the standard protocol and thephasesof the cell cycle
were determined by FACScan analyses after PI staining of DNA; M1=G1 /G0 ( gap 1, interval between mitosis and DNA replication ); M2=S ( synthesis of DNA );
M3=G2 /M (gap 2, preparation for cell division ); M4=subdiploid, apoptotic cells or DNA -containing, countable subcellular particles. (A ) Control cells treated with
vehicle only; (B ) cells incubatedwith 100nMDex for the final 48hours; (C ) cellswere cultured for 72hourswith 0.5mMDFMO; (D ) cellswere cultured for 72 hourswith
0.5 mMDFMO plus 100 nMDex for the final 48 hours; (E ) cells were cultured for 72 hours with 0.5 MMGBG; (F ) cells were cultured for 72 hours with 0.5 MMGBG
plus 100 nMDex for the final 48 hours; (G ) cells were cultured for 72 hourswith 0.5mMDFMOplus 0.5MMGBG; and (H ) cellswere cultured for 72 hourswith 0.5mM
DFMO plus 0.5 M MGBG plus 100 nM Dex for the final 48 hours. All data were collected after 72 hours in culture. The data shown are from one experiment.
Reproducible results were obtained for each variable in two to three experiments. The percentages of cells in each compartment are presented in Table 1.
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cells with impaired depolarized mitochondrial membranes
were detected using a 530-nm filter and viable red cells with
a 585-nm filter.
Cell Cycle Evaluation by Propidium Iodide (PI) Staining
Cells (1106) were pelleted at 250g for 10 minutes at 48C
and resuspended one time in 1 ml of 48C PBS/0.1% sodium
azide solution and transferred to 1.5-ml microtubes. The
cells were collected at 250g for 5 minutes at 48C and
supernatants removed, and then were suspended in low salt
stain [3% polyethylene glycol 8000, 50 g/ml PI, 4 mM
sodium citrate (Mallinckrodt, Hazelwood, MO), plus 0.1%
Triton X-100 (Bio-Rad) and 180 U of RNAse A (Worthing-
ton Biochemicals, Lakewood, NJ) ]. They were then incu-
Figure 5. Acceleration of apoptosis following sequential treatment with DFMO plus MGBG followed by Dex. CEM-C7 -14 cells were treated according to the
standard protocol and the cellular DNA determined by PI staining and FACScan analyses. (A,B ) Forty and 48 hours of 100 nM Dex treatment. (C,D ) Twenty - four
hours of polyamine pathway inhibitors and 24 or 35 additional hours with 100 nMDex added. The percentages of cells in each compartment are presented in Table 2.
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bated in a 378C water bath in the dark for 20 minutes. An
equal volume of high salt stain (3% polyethylene glycol 8000,
50 g/ml PI, 400 mM sodium chloride, 0.1% Triton X-100)
was added. The samples were covered and placed at 48C for
at least 1 hour in the dark. Sample lots of 20,000 cells were
analyzed for DNA content by flow cytometry. Red (PI) was
detected using a 585-nm filter. Cells containing subdiploid
DNA were not used for determination of percentages in G1/
G0, S, or M phase.
Results
Dex Suppresses ODC
In earlier studies, we had demonstrated that by 4 days of
exposure, 1 M Dex substantially kills most CEM-C7 cells
[30], with DNA fragmentation appearing between 36 and
48 hours [31]. Due to repression of c-myc transcription,
levels of c-myc mRNA begin to be suppressed as early as
1 hour after addition of Dex [19,20]. We tested the effect of
1 M Dex alone on ODC levels in CEM-C7 cells over
48 hours. The data of Figure 1;A C demonstrate that ODC
activity (A), mRNA (B), and protein (C) were all suppressed,
whereas ODC activity remained relatively constant through-
out the measured time course in control cells (Figure 1A ).
ODC mRNA was reduced by 8 hours and strongly so by
16 hours and beyond (Figure 1B ). ODC protein levels were
clearly reduced as well (Figure 1C ).
Effects of Dex and Inhibitors of Polyamine Synthesis on
Polyamine Levels in CEM Cells
In preliminary control experiments (not shown), we
established in detail that the levels of each of the three
polyamines assayed at 24-hour intervals remained relatively
constant in untreated CEM cells. Over the course of
72 hours, putrescine and spermine fluctuated within the
range of 10 to 25 pmol /105 cells, spermidine in the range of
35 to 45 pmol /105 cells. For example, Figure 2, panels A
and B) show data for control CEM-C7-14 cells in logarith-
mic growth at 48 and 72 hours after addition of vehicle to the
cultures. Further preliminary experiments following the
effects of adding DFMO or MGBG singly revealed that
DFMO alone reduced putrescine to undetectable levels by
24 hours and spermidine to undetectable levels by 48 hours
(not shown); MGBG alone dramatically elevated putrescine
levels by 48 hours with a marked reduction in spermidine
and spermine levels (not shown). The combination of both
inhibitors, however, effectively lowered the levels of all three
polyamines (Figure 2; A and B ). Although this slowed cell
growth considerably, it caused little cell death (Figures
3A and 4G ). We therefore tested the inhibitors in combina-
tion with Dex. After preliminary studies comparing the effects
of adding the inhibitors and Dex simultaneously or sequen-
tially, we chose the following protocol, which was used for the
data in Figures 2 7 ). Cultures were divided and treated at
time zero with vehicle only (control ) or 0.5 mM DFMO plus
0.5 M MGBG. Twenty- four hours later, subsets of control
and inhibitor - treated cells received 100 nM Dex. Samples
for polyamine analysis or viability were taken at several
times thereafter. Polyamine data from such experiments on
CEM-C7-14 cells are shown in Figure 2;A and B ),
demonstrating that after 48 hours of Dex treatment alone,
putrescine levels were significantly lowered (P=.045), but
there was no statistically significant effect on spermidine or
spermine concentrations. Adding Dex 24 hours after both
inhibitors caused insignificant effects in addition to those
caused by DFMO plus MGBG for 48 hours (Figure 2A ). By
72 hours in the inhibitors plus 48 hours in Dex, putrescine
levels remained undetectable; spermidine, however, was
elevated well over the undetectable levels found after
inhibitors alone for the same total time of 72 hours, whereas
spermine was increased but not to a significant extent
(Figure 2B ).
CEM-MycER-22 is a clone of CEM-C7-14 that has been
stably transfected with an expression vector for c-myc. In
these cells, the hybrid MycER protein, which conveys c-Myc
functions, is constitutively expressed [32]. These cells
exhibit a marked resistance to cell death after 48 hours in
100 nM Dex, compared to the parental CEM-C7-14 clone
(Ref. [32], also Figure 6 ). To test the dependence of
polyamine levels on c-Myc in the face of the drug
combinations, we carried out the standard protocol on
CEM-MycER-22 cells. The putrescine pool was not elevated
significantly in the CEM-MycER-22 cells, compared to the
CEM-C7-14 cells under the control conditions, but the
remaining downstream polyamines were elevated (compare
controls, Figure 2; A and B with C and D ). DFMO and
MGBG reduced polyamine levels, but not as dramatically
as in the CEM-C7-14 cells. In the CEM-MycER-22 cells,
Dex alone for 48 hours lowered putrescine significantly
(Figure 2D ), P=.02 but not the other two polyamines,
compared to time-matched controls. Comparison of poly-
amine levels in CEM-MycER-22 cells exposed to inhibitors
only with those exposed to inhibitors plus Dex revealed a
significant difference in spermidine levels (Figure 2D ),
Figure 6. Constitutive expression of an active form of c -Myc gives little or no
protection against Dex - induced apoptosis in polyamine depleted cells. CEM-
C7 -14 and CEM-MycER-22 cells were treated according to the standard
protocol and the number of viable cells was determined by trypan blue dye
exclusion at 0, 24, 48, 72, and 96 hours DFMO and MGBG were added at 0
time and 100 nM Dex was added at 24 hours ( indicated by the arrows ). Error
bars represent 1 SD limits; where no bars are seen, the standard deviation fell
within the size of the symbol, n=3.
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DF+MG versus DF+MG+Dex, P=.002) at 72 hours of
treatment. As in CEM-C7-14 cells, the addition of Dex to
the inhibitors in CEM-MycER-22 cells tended to raise
spermidine levels at 72 hours, with no effect over that of
inhibitors alone on putrescine and spermine (compare
Figure 2;B and D ). At both 48 and 72 hours, the levels of
spermidine and spermine were greater in the CEM-
MycER-22 cells receiving DFMO plus MGBG and DFMO
plus MGBG plus Dex than in the corresponding wild- type
CEM-C7-14 cells (Figure 2; A versus C ;B versus D ). As
will be seen below, the higher polyamine levels in CEM-
Myc-22 cells did not afford strong protection against the
three-drug combination.
The Extent and Onset of Apoptotic Cell Death Enhanced by
the Combination of Polyamine Pathway Inhibitors and
Glucocorticoid
At the concentrations used, the combined effect of DFMO
and MGBG was primarily to slow cell growth, lengthening the
doubling time from 24 to 48 hours. Figure 3A ) demonstrates
the growth- inhibitory effects on the CEM-C7-14 clone of the
two inhibitors together without Dex for 72 hours, 100 nM Dex
alone for 48 hours, and that after 72 hours when Dex was
added after 24 hours of DFMO plus MGBG. The vehicle-
treated control cells continued to grow logarithmically
through the course of the experiment. Exposure to Dex
alone reproducibly caused cell loss beginning only beyond
24 hours and still incomplete at 48 hours ( the time points
indicated as 48 and 72 on the abscissa). This is consistent
with earlier, longer time course studies showing the full
extent of Dex-evoked apoptosis [30,31]. When Dex was
added after 1 day of exposure to the polyamine pathway
inhibitors, cell loss began earlier than with Dex only and was
more extensive during the subsequent 48 hours (compare in
Figure 3A, , and  curves; see also Figure 6 ).
The cell loss seen in Figure 3A caused by the three-drug
combination appeared to be apoptotic. Glucocorticoids alone
are a well -known cause of lymphoid cell apoptosis, but the
consequences of adding the polyamine inhibitors and
glucocorticoids have had only limited evaluation [23].
Morphologically, the cells appeared to shrink, condense,
and lyse (not shown). Phosphatidylserine eversion to the
outer surface of the plasma membrane has been shown to
precede loss of cell viability [33] and can be assayed by
Annexin binding. Early apoptotic cells exclude 7-AAD;
therefore, Annexin-positive, 7-AAD–negative cells have
undergone phosphatidylserine membrane eversion, but still
have an intact cell membrane. By flow cytometry, with Dex
alone, 5% of the cells were Annexin-positive, 7-AAD–
negative at 59 hours, 35 hours after addition of Dex (Figure
3B ); but if the cells were first exposed to the polyamine
pathway inhibitors for 24 hours, this number increased to
21%.
Both Dex and MGBG have been reported to affect
mitochondrial functions adversely [34-36]. We therefore
tested for this by use of the dye JC-1, which freely enters
cells, where it produces a green fluorescence, unless taken
up by active mitochondria, which metabolize it to its red,
aggregate form. This conversion requires an intact mito-
chondrial membrane potential,m. Cells that remain green
have lost mitochondrial membrane integrity, which causes
release of activators of the caspase-3 apoptotic pathway
[35]. By this assay, the polyamine pathway inhibitors at
these concentrations had little effect (Figure 3C ). In Dex
alone, no change was seen until 64 hours, after which a
sharp drop in cells staining red was seen (note interval 64 to
72 hours; Figure 3C ). When Dex was added 24 hours after
the polyamine pathway inhibitors, a two-stage effect on
mitochondria was seen. Starting at 48 hours, intact
mitochondrial fluorescence was reduced by 10% to 15%,
followed by an even deeper decrease between 59 and
64 hours (Figure 3C ).
For a third test of apoptosis, CEM-C7-14 cells treated
according to the standard protocol were evaluated by
staining their DNA with PI at the 72-hour time point.
Figure 4 and Table 1 show FACScans and percent gated
cells from such an experiment. The control panel (Figure 4A )
illustrates a population of logarithmically growing cells after
72 hours of exposure to vehicle only, with about 98%
viability. After 48 hours in 100 nM Dex alone, 24% of the
cells had a subdiploid DNA content, typical of apoptosis
(Figure 4B ) and Table 1), and among the remaining
cells, the percentage in G1/G0 increased to 67%. We
have observed [30] and others have confirmed this
accumulation of CEM cells in G1/G0 due to Dex [18].
After 72 hours, 0.5 mM DFMO, 0.5 M MGBG, or both
combined in no case produced more than 13% apoptotic
CEM-C7-14 cells (Figure 4;C;E ;G ) and Table 1). DFMO
for 72 hours, with Dex as well during the final 48 hours,
resulted in somewhat greater numbers of subdiploid cells
than with Dex alone for 48 hours (30% as compared to 24%;
Figure 4;B and D and Table 1). By 72 hours, however,
the three-drug treatment had killed nearly the entire
culture, with extensive DNA breakage (Figure 4H ).
Pretreatment with Polyamine Pathway Inhibitors Followed
by Dex Causes Early Induction of Apoptosis
The sequential combination of polyamine pathway inhib-
itors, followed by addition of Dex, resulted in a noticeable
increase in subdiploid cells compared to that seen after
24 hours of Dex alone. At that time, 18% of the cells receiving
the combination contained subdiploid amounts of DNA,
compared to 2% after Dex alone for a comparable period
(data not shown). This acceleration of apoptosis due to the
sequential combined treatment is shown by the data in
Figures 3; 5 and 6. In Figure 5 and Table 2, the time in Dex
Figure 7. PI analyses of CEM-MycER-22cells after three - drug treatment. CEM-MycER-22 cells were treated according to the standard protocol, stained with PI,
and analyzed by FACScan after the intervals indicated. The data shown are from one of two experiments, which gave very similar results. The percentages of cells in
each compartment are presented in Table 3, A and B.
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required for an equivalent accumulation of PI-stained
subdiploid cells is compared after addition of Dex alone
(Figure 5;A and B ) or Dex subsequent to DFMO and
MGBG. As the data show, pretreatment with DFMO and
MGBG followed by 24 hours of added Dex produces the
amount of cell death caused after 40 hours of Dex alone
(Figure 5;A versus C ); 35 hours of Dex following the
polyamine inhibitors result in kill equivalent to 48 hours of
Dex alone (Figure 5;B versus D ). The accelerating effect
on reduction of numbers of the leukemic cells is shown by the
curves with open symbols in Figure 6. The combined,
sequential treatment results in significantly reduced numbers
of cells 24 hours after Dex is added ( triangles), whereas Dex
alone begins to show an effect between 48 and 72 hours
after addition (squares). Furthermore, the extent of cell loss
is greater at each of the time points. In Dex alone, equivalent
total cell loss is reached only 1 to 2 days later [30].
Constitutive Expression of c-Myc Does Not Protect Against
Dex in Polyamine-Depleted Cells
We have shown that expression of the hybrid protein c-
MycER confers significant resistance of CEM cells to Dex-
induced apoptosis. The chimeric gene, Myc-ER, is
expressed constitutively in these cells, and the Myc moiety
is functional although the ER is not activated by estrogen
[32]. Because the ligand-binding domain of the ER may be
activated by nonsteroid effectors, we suspect that some
endogenous ligand or interactive pathway chronically
activates the chimera. In CEM-MycER-22 cells, the ODC
mRNA-lowering effect of Dex alone is blunted but not
completely blocked (data not shown). To determine
whether polyamine pathway manipulation could sensitize
cells, which stably produce an active form of c-Myc, we
compared the effects of the standard protocol on CEM-
MycER-22 with those on CEM-C7-14 cells (Figure 6 ). Dex
alone caused a six - fold reduction in viable CEM-C7-14
cells 3 days later (open squares). CEM-MycER-22 cells
identically treated were reduced only 2.5- fold (closed
squares), reproducing the protective effect of constitutive
c-Myc expression that we have reported [32]. Pretreatment
with DFMO and MGBG for 1 day, followed by 3 days with
Dex added, caused extensive additional apoptosis of both
CEM clones (open and closed triangles). Clearly, the
protective effect of MycER expression was largely over-
come, although there were somewhat more viable cells
remaining after 96 hours in the CEM-MycER-22 flasks than
in the CEM-C7-14 flasks. Figure 7 and Table 3, A and B
show data for CEM-MycER-22 cells stained with PI at two
time points after various treatments. Again the protection
against Dex alone in these cells is shown (compare Figure
4; Panel B with upper right panel, Figure 7, and Table 1
with Table 3A). There were clear synergistic effects,
however, between the polyamine inhibitors and Dex on the
CEM-MycER-22 cells, and these effects overcame the
protection to Dex afforded by constitutive c-Myc expression.
In sum, apoptosis was considerably increased with the
three-drug treatment as compared to Dex treatment alone in
both CEM-C7-14 and CEM-MycER-22 cells (Figures
3A; 4; 6 and 7 and Tables 1 and 3, A and B). CEM-C7-14
cells showed more sensitivity to the three-drug treatment
than CEM-MycER-22, but synergy was clearly indicated in
both cell lines.
Discussion
As hypothesized, glucocorticoids reduce ODC mRNA levels,
protein, and enzymatic activity, in a time sequence consis-
tent with dependence on c-Myc. However, under our
experimental conditions, this reduction in activity and content
of ODC caused only a 50% reduction in putrescine levels
( the immediate product of ODC), whereas the downstream
polyamines spermidine and spermine increased during the
time frame in which Dex proceeded to initiate apoptosis.
Thus, we conclude that in this system, a reduction in total
polyamine levels is not the key linear consequence of Dex
administration that leads to apoptosis.





















G1 /G0 53.4 62.1 53.8 57.2 67.0 63.8 65.3 58.7
S 31.7 25 30.7 23.1 20.4 22.3 21.2 32.9
M 14.8 12.8 15.5 19.5 12.3 13.9 13.5 8.4
Apoptotic 1.7 4.4 2.9 12.8 24.4 30.0 23.4 76.2











G1 /G0 58.6 67.0 66.8 63.1
S 23.9 20.4 19.1 20.9
M 16.5 12.3 14.1 15.9
Apoptotic 6.8 24.4 6.5 25.3
78 Synergism of Glucocorticoid /Polyamine Inhibitors Miller et al.
Neoplasia . Vol. 4, No. 1, 2002
As to why the polyamine levels remained elevated when
the rate- limiting enzyme had been sharply reduced, one
suggestion is that AdoMetDC remains active, feeding into
the polyamine pathway beyond ODC, thus contributing to the
formation of the downstream polyamines. Thus, until
exhausted, the existing putrescine pool could be used to
maintain spermidine and spermine. If the cells act to maintain
the downstream polyamine levels (by whatever mecha-
nism), it suggests that these must be important and perhaps
even protective against the apoptotic process initiated by the
glucocorticoid. Consequently, we investigated further the
effect of inhibitors of the polyamine pathway alone and in
conjunction with Dex.
We first carried out extensive tests on the inhibitors
DFMO and MGBG singly, DFMO to inhibit ODC, and MGBG
to prevent AdoMetDC production. In experiments not shown
here, we found that DFMO slowly decreases the putrescine
and spermidine pools, while initially increasing that of
spermine, the final product of the pathway. By 48 hours in
DFMO alone, putrescine and spermidine were undetectable,
whereas spermine had increased somewhat over control
levels. After 60 hours or later in DFMO, spermine as well fell
to control levels or slightly below. We found that if addition of
glucocorticoid was delayed until polyamine pools had been
decreased by DFMO, some synergy could be seen in the
apoptotic effect. Thus, in our clonal system, we confirm the
basic finding of synergism that was described by Choi et al.
[23], on uncloned CEM cells, though the kinetics and extent
of the effect seem to differ in the two related experimental
cellular systems. We found it difficult to obtain consistent
results, however, with the DFMO plus Dex combination.
Treatment with MGBG has two effects on polyamines.
The inhibitor blocks AdoMetDC and therefore the subse-
quent amino propyl additions to the pathway. It is also
known that MGBG blocks the transport system through
which spermine and spermidine enter the cell. In addition,
MGBG can cause mitochondrial damage [36]. This effect
is closely dose-dependent. Consequently, we conducted
extensive preliminary studies to find the minimum effective
concentration of MGBG that in combination with DFMO
would reduce polyamine levels without causing overt cell
death. We found this concentration to be approximately
0.5 M, a level of the order of magnitude that in mouse
leukemic L1210 cells has been shown to cause only slight
mitochondrial swelling [36]. In our CEM-C7-14 cells, tests
with the dye JC-1 indicated that the combination of 0.5 M
MGBG and 0.5 mM DFMO had no effect on mitochondrial
integrity for up to 72 hours (Figure 3C ) and only a slight
effect after 96 hours.
Studies in which the polyamine pathway inhibitors were
added simultaneously with Dex showed weak synergism at
the times we investigated. The two polyamine pathway
inhibitors, singly or combined, caused only a sustained low
level of apoptosis. However, addition of the inhibitors long
enough to cause significantly lowered polyamines, followed
by Dex, resulted in marked synergy. This was seen both as
a more rapid onset of apoptosis and as more extensive cell
death. We find a general correlation between lowered
polyamine levels and enhanced sensitivity to Dex. However,
CEM-MycER-22 which we engineered to maintain c-Myc
and therefore ODC, showed less reduction of polyamines
but only modest— if any— protection against the three-
drug combination. Together, our results suggest that a
chronic effect of treatment by DFMO and MGBG is to make
the cells more sensitive to the glucocorticoid Dex. Lowering
total cellular polyamine levels does not seem to be the
entire explanation for this synergy. It may be that organelle-
specific polyamine reductions or nonpolyamine related
effects are relevant. It has been proposed, for example,
that the critical apoptotic action of Dex is to cause a loss of
mitochondrial membrane integrity [34,35]. Thus, the reduc-
tion in cell polyamines, and in particular that of mitochon-
drial polyamines due to MGBG [37], may make those
organelles particularly susceptible to Dex. In CEM-MycER-
22 cells, MGBG could have a disproportionate effect on
mitochondrial polyamines undetectable in the total poly-
amine pool. It is also possible that other mechanisms
account for the lack of protection in these cells. The
mechanism of the Dex effect on mitochondria is unknown,
though it presumably requires synthesis of both RNA and
protein because blocking these processes protects lym-
phoid cells from glucocorticoid- induced apoptosis [17,38].
Thus, MGBG, together with DFMO, in a time-dependent
manner, renders mitochondria and cells more susceptible to
the apoptosis consequent on the altered gene expression
induced by Dex.
Many preclinical and clinical cancer trials of DFMO,
MGBG, and the combination have been conducted over the
Table 3. Percent of Cells Gated into Cell Cycle Compartments or Apoptotic from Experiment in Figure 7.
Cell Cycle Percent Gated Control DFMO+MGBG 100 nM Dex DFMO+MGBG+100 nM Dex
(A ) 72 hours inhibitors, 48 hours Dex
G1 /G0 59.9 62.4 59.3 33.4
S 20.9 16.3 16.7 11.5
M 16.5 17.3 15.2 12.4
Apoptotic 2.7 4.0 8.8 42.6
(B ) 96 hours inhibitors, 72 hours Dex
G1 /G0 62.5 67.9 48.3 11.1
S 20.3 16.9 8.6 4.4
M 16.2 14.1 9.2 2.6
Apoptotic 0.8 1.0 30.6 77.8
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years, with varying degrees of success. DFMO and Dex are
considered to be relatively nontoxic [39,40]. MGBG origi-
nally showed promise in clinical trials, but was temporarily
abandoned due to toxicity [41,42]. After pharmacokinetic
studies showed it to have an extraordinary long half - life in
vivo, new dose schedules allowed MGBG to return to clinical
usage [41,42]. In recent phase II trials, the drug showed
potential, with little toxicity against AIDS-related lymphoma
[43]. DFMO and MGBG, in combination, have been shown
to be effective in preclinical and clinical trails, though care
must be taken in dosage and schedules if undue toxicity is to
be avoided [41,42]. Our three-drug combination in vitro
suggests that due to the synergy between the polyamine
pathway inhibitors and Dex, use of lower, less toxic amounts
of MGBG may be possible. MGBG dosage seems to be the
main factor in using the polyamine inhibitor drug combination
effectively. We show that a subtoxic concentration of MGBG
is effective when combined with DFMO plus Dex. This
concentration of MGBG does not cause the mitochondrial
membrane to depolarize significantly compared to untreated
controls (Figure 3C ). The low level of toxicity due to the
polyamine pathway inhibitors alone, seen in CEM-C7-14
cells, is not present in CEM-MycER-22 cells, indicating that
at those concentrations, the inhibitors themselves are not an
indiscriminate cause of cell death and that the higher
polyamine levels in these cells may afford protection (see
Figures 4G and 7 ) Rizzo et al. [43 ] were able to estimate
tissue levels of MGBG from one patient with AIDS-related
non-Hodgkin’s lymphoma who had been treated on a
schedule of 600 mg/m2 MGBG intravenously on days 1
and 8. Two days after the day 8 dose, the patient expired and
his tissues were analyzed [43]. On a microgram-of-MGBG-
per-gram-of- tissue-wet-weight basis, it can be calculated
that the tissue concentrations were of the same order of
magnitude as those used herein. It is possible that
appropriate protocols of these three drugs may provide a
combined chemotherapeutic response of value in certain
lymphoid malignancies.
The combined data from our studies suggest that the
lethal pathway evoked by glucocorticoids does not employ
lowering of polyamines as a necessary and sufficient step.
However, polyamines are protective against Dex, and
preliminary administration of DFMO and MGBG renders
cells more sensitive to the lethal effect of the glucocorticoid.
Regardless of precise mechanism, our data suggest the
possibility that the three drugs employed here might prove a
potent combination in therapeutic circumstances.
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